Invention Summary
Risk assessment in multiple
myeloma is important to direct clinical treatments. Investigators at the University of Utah
have developed a new gene model, the MM
Survival Index14 (MMSI14) for
classification of multiple myeloma. The MMSI14 is the first gene
expression signature focused on both low-risk and high-risk disease. An initial study using multivariate
comparative analysis confirms that MMSI14 is the best available model to predict
clinical outcome in MM patients.
Features and Benefits
- The MMSI14 is the only
gene expression signature to give actionable information on both low and high
risk disease in multiple myeloma.
- The MMSI14 appears to
have superior prognostic power compared to gene signatures currently being
applied for classification of multiple myeloma.
- Clinical application of
the MMSI14 will provide information needed to design the optimal therapy for
patients, enabling truly personalized treatment.
Market Opportunity
Multiple myeloma is the
second most common hematological malignancy in the United States. Despite remarkable improvements in the
treatment over the past decade, clinical management of this disease remains
challenging. Defining both low-risk and
high-risk disease is crucial for determining optimal therapies for specific risk
groups.
Intellectual
Property: A provisional patent application is
pending.
Inventors: Dr. Maurizio Zangari, Dr.
Tiehua Chen.
Related
Publications: Chen
et al , ¿Low-risk identification in multiple myeloma using a new 14-gene model¿,
Eur J. Haemotol. 2012, 90:28-36.
